Market Overview:
The global diabetic neuropathy treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of diabetes, rising geriatric population, and technological advancements in the field of diabetic neuropathy treatment. Based on type, the global diabetic neuropathy treatment market is segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. Peripheral Neuropathies are further sub-segmented into sensory nerve damage (painful feet), motor nerve damage (weakness or paralysis), and autonomic nerve damage (digestive problems). Autonomic Neuropathies are further sub-segmented into cardiovascular autonomic dysfunction (CAD), gastroparesis, bladder dysfunction syndrome (BDS), postural hypotension syndrome (PHS) and erectile dysfunction/sexual dysfunction. Proximal Neuropathies are further sub-segmented into mononeuropathies and polyneuropathies. Based on application, the global diabetic neuropathy treatment market is segmented into hospitals & clinics settingsand others settings such as research institutes & academic centers,. Hospitals & clinics setting held a dominant share in 2017 due to increasing number of patients with diabetes seeking medical assistance for their condition.
Product Definition:
Diabetic neuropathy is a complication of diabetes that affects the nerves. It can cause numbness, tingling, pain, and weakness in the feet and legs. Treatment aims to control blood sugar levels and manage any associated symptoms.
Peripheral Neuropathy:
Peripheral neuropathy is a rare and chronic disorder of the peripheral nervous system. It is an area-specific degenerative disease that affects the nerves that exit from the spinal cord and enter into different parts of body such as arms, legs, feet, etc. The nerve damage may occur due to several reasons such as diabetes (both type I & II), HIV infection or other autoimmune diseases like lupus or scleroderma.
Autonomic Neuropathy:
Autonomic neuropathy is a type of diabetic neuropathy that affects the nerves that control the automatic functions of the body such as digestion, heart rate, blood pressure and temperature. It is one of the most common complications associated with diabetes mellitus. According to statistics published by International Diabetes Federation in 2019, around 463 million people are living with diabetes globally and this number will increase to 700 million by 2045.
Application Insights:
The others application segment held the largest share of over 60.0% in 2017. The others application category includes private practices, home healthcare and other non-clinical settings such as social services and rehabilitation centers. Increasing cases of diabetes are driving the need for diabetic neuropathy treatment in clinics and hospitals which is expected to drive growth over the forecast period. However, due to lack of awareness about available treatments among patients preferring self-treatment at home or opting for early hospital discharge due to financial constraints will hamper market growth during the study period thereby creating lucrative opportunities for players operating in this space.
Regional Analysis:
North America dominated the global diabetic neuropathy treatment market in 2017. This can be attributed to the presence of a large patient pool, high awareness levels coupled with advanced healthcare infrastructure and availability of effective treatment options for patients suffering from diabetes. In addition, rising prevalence of diabetes-related disorders such as autonomic neuropathy and peripheral neuropathy is expected to fuel growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to improving healthcare facilities in emerging countries like India and China along with growing investments by major pharmaceutical companies for launching new products in these regions. Moreover, increasing disposable income levels are also estimated to contribute towards regional market development during the same period. Furthermore, government initiatives encouraging people suffering from chronic diseases are also expected favorably impact regional demand during 2018 - 2030 time frame.
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is primarily because of the changing lifestyle and dietary habits. As a result, the number of people suffering from diabetic neuropathy is also on the rise.
- Growing awareness about diabetic neuropathy: There is growing awareness among people about diabetic neuropathy and its symptoms. This has led to an increase in the number of people seeking treatment for this condition.
- Advances in technology: There have been significant advances in technology over the past few years that have helped improve diagnosis and treatment options for diabetic neuropathy patients. This has led to an increase in their acceptance among patients worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Diabetic Neuropathy Treatment Market Research Report
By Type
Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy
By Application
Hospitals, Clinics, Others
By Companies
Abbott, Roche, Eli Lilly, Johnson & Johnson, GlaxoSmithKline, Lupin, Glenmark, Depomed, Astellas, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
185
Number of Tables & Figures
130
Customization Available
Yes, the report can be customized as per your need.
Global Diabetic Neuropathy Treatment Market Report Segments:
The global Diabetic Neuropathy Treatment market is segmented on the basis of:
Types
Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott
- Roche
- Eli Lilly
- Johnson & Johnson
- GlaxoSmithKline
- Lupin
- Glenmark
- Depomed
- Astellas
- Pfizer
Highlights of The Diabetic Neuropathy Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Diabetic Neuropathy Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Diabetic neuropathy treatment is a combination of medications and physical therapy to help improve the symptoms of diabetic neuropathy. Treatment may include: medications to control blood sugar levels, such as insulin or oral diabetes medications physical therapy to improve muscle function and reduce pain
Some of the key players operating in the diabetic neuropathy treatment market are Abbott, Roche, Eli Lilly, Johnson & Johnson, GlaxoSmithKline, Lupin, Glenmark, Depomed, Astellas, Pfizer.
The diabetic neuropathy treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Diabetic Neuropathy Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Diabetic Neuropathy Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Diabetic Neuropathy Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Diabetic Neuropathy Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Diabetic Neuropathy Treatment Market Size & Forecast, 2020-2028
4.5.1 Diabetic Neuropathy Treatment Market Size and Y-o-Y Growth
4.5.2 Diabetic Neuropathy Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Peripheral Neuropathy
5.2.2 Autonomic Neuropathy
5.2.3 Proximal Neuropathy
5.2.4 Focal Neuropathy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Diabetic Neuropathy Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Diabetic Neuropathy Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Peripheral Neuropathy
9.6.2 Autonomic Neuropathy
9.6.3 Proximal Neuropathy
9.6.4 Focal Neuropathy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Peripheral Neuropathy
10.6.2 Autonomic Neuropathy
10.6.3 Proximal Neuropathy
10.6.4 Focal Neuropathy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Peripheral Neuropathy
11.6.2 Autonomic Neuropathy
11.6.3 Proximal Neuropathy
11.6.4 Focal Neuropathy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Peripheral Neuropathy
12.6.2 Autonomic Neuropathy
12.6.3 Proximal Neuropathy
12.6.4 Focal Neuropathy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Peripheral Neuropathy
13.6.2 Autonomic Neuropathy
13.6.3 Proximal Neuropathy
13.6.4 Focal Neuropathy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Diabetic Neuropathy Treatment Market: Competitive Dashboard
14.2 Global Diabetic Neuropathy Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott
14.3.2 Roche
14.3.3 Eli Lilly
14.3.4 Johnson & Johnson
14.3.5 GlaxoSmithKline
14.3.6 Lupin
14.3.7 Glenmark
14.3.8 Depomed
14.3.9 Astellas
14.3.10 Pfizer
